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the HN site, but binding of the transition state analog Peter M. Colman and Brian J. Smith
Walter and Eliza Hall Institute of Medical Researchtriggers major changes (see Table). In particular, Y6
(Y526 in that structure) is one of the residues associated 1G Royal Parade
Parkville, Victoria 3050with the functional switch, and its movement also
causes rearrangement of I175, the structural analog of Australia
E1 in the Figure. Thus, unlike the enzymes with sialidase
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In the last 5 years, tremendous insight into antigen
recognition has been gained through the determinations
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of structures of a number of TCRs complexed to pep-
tide-MHC, in both mouse and human systems (1, 2).
The crystal structure of a human T cell receptor, which These initial structures solved a number of longstanding
is used almost exclusively in the immune response to global questions, such as the diagonal TCR/pMHC
an Epstein-Barr virus protein, highlights the impor- docking orientation, which appears to be conserved, to
tance of noncontact residues in antigen recognition. some degree, across all TCR/pMHC interactions. While
these early structural revelations were dramatically in-
formative, most fundamental questions about T cell rec-The cellular branch of immune surveillance is governed
by the recognition of major histocompatibility complex ognition still await more detailed structural studies. One
of these questions concerns the phenomenon of “bias”(MHC)-bound peptide antigens by  T cell receptors
(TCR) on T cells. As for antibodies, the TCR is assembled in a given TCR response to antigen. Certain antigens
elicit only a very limited set of TCR sequences, whichcombinatorially from a vast array of  and  chain vari-
able region genes that endow it with an almost limitless recognize it as a processed peptide in the context of
MHC, rather than a broad and diverse set of  TCRpotential for diversity. In particular, most of this se-
quence variation is concentrated in centrally located sequences (3). The assumption has been that the sol-
vent-exposed peptide antigen recruits highly specificcomplementarity-determining region-3 (CDR3) antigen
binding loops, where diversity is amplified at the junc- TCR contact residues that reappear within the context
of different TCR  chain combinations to achieve rec-tions of the Variable (V) gene segments with the Diversity
(D) and Joining (J) regions, along with nonnucleotide ognition. However, since a structure of a highly biased
TCR has not yet been reported, the underlying molecularencoded additions (N- and P-additions). For a given
antigen, many different TCR sequences can be pro- basis for these biases has remained speculative.
In this issue of Structure, Kjer-Nielsen et al. report theduced which are equally effective at recognizing a single
peptide-MHC complex (pMHC). In fact, in a normal im- high-resolution crystal structure of a “public” human 
TCR that is almost invariant in the response of HLA-Bmune response to antigen, one usually finds that no
one, individual TCR sequence dominates the population individuals to Epstein-Barr virus EBNA 3 antigen (4). EBV
is a very prevalent member of the herpesvirus family,of T cells directed at the invading pathogen.
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and establishes a latent viral infection in up to 90% of ing” mutations in the mature antibody were located in
framework positions outside the antigen binding site.adults. Fortunately, we generate a robust cellular and
humoral immune response to EBV, so the virus remains Similar to the LC13 TCR, these mutations were playing
a critical role in determining the structures of the CDRdormant and virtually unnoticed in most of us, unless
one is immunocompromized. The fact that our cellular loops through both direct and indirect effects. The struc-
tural role of residues outside the antigen binding siteimmune system contains EBV so well using a biased
TCR repertoire, while other viral infections are not sub- has been well known to the protein engineering commu-
dued by more diverse responses, underscores the ne- nity for quite some time. Initial efforts to swap CDR
cessity for a close examination of the structure of a loops from mouse to human antibodies, in an effort to
biased TCR. The crystal structure of the LC13 TCR, then, produce therapeutically useful “humanized” antibodies,
provides a number of interesting and subtle new insights resulted in the loss of antigen binding affinity in the
into the phenomenon of chain bias. engineered variant. Antigen binding activity could be
Kjer-Nielsen et al. report the structure of a complete rescued by mutation of framework residues supporting
human  heterodimer at 1.5 A˚ resolution, which allows the CDR loops.
a view, in near atomic detail, of the inter- and intramolec- A final issue that will require the structure of the LC13
ular interactions that are unique to TCR structures in complexed with its peptide-MHC ligand is the issue of
comparison to other immune receptors. This type of CDR loop conformational change. There are a number
detail is vital to elucidate the subtle structural features of cases now where large-scale CDR loop movements
that might explain why this particular TCR is almost have been seen to accompany MHC recognition (1). In
exclusively used to respond to EBV. The principal finding fact, these large loop movements are almost certainly a
of this paper is that not only are the most solvent- further, non-germline-encoded mechanism to increase
exposed residues of the CDR loops invariant in this TCR, the crossreactivity of a TCR. In the LC13 structure, it is
but many of the conserved residues are buried within noted that most of the CDR loops do not fall within
the antigen combining site in locations which are not known structural families, or “canonical” CDR loop con-
likely to participate directly in peptide-MHC recognition. formations. The authors speculate that these unusual
Hence, the bias is not simply a function of TCR contact conformations may be a key to understanding the chain
residues forming highly preferred interactions with the bias. However, in the absence of a complex, it is impossi-
ligand, but underlying structural influences on the CDR ble to know the final bound structure of these loops.
loop conformations are necessary for the presentation We eagerly await a snapshot of this interesting TCR
of the contact residues in very defined structural con- complexed to its ligand.
texts. These two different aspects of the TCR structure
are, then, intimately interrelated. Consider that the in-
Erin J. Adams and K. Christopher Garciavariant nature of the LC13 sequence is repeatedly se-
Department of Microbiology & Immunologylected for out of 1012 other possibilities. In fact, there
Department of Structural Biologyis a convergence on the CDR3 amino acid sequences
Stanford University School of Medicineof LC13 even though it is arrived at through entirely
Stanford, California 94305different genetic mechanisms in different individual TCR
clones. This speaks of an astounding biological pressure
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Periplasmic Chaperones—New
Structural and Functional Insights ture of the periplasmic chaperone SurA.
It is well established that productive protein folding in
the cell requires the assistance of molecular chaper-Although chaperones exist in the periplasmic com-
partment of Gram-negative bacterial cells, how they ones. The mechanisms of action of chaperones residing
